Drug recall · August 30, 2023
Rufinamide Tablets recall
Why: cGMP deviations: Batch was released prior to approval.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Rufinamide Tablets, USP 400 mg, packaged in 120-count bottle, Rx only, Distributed by: Aurobindo Pharma USA, Inc., 279 Princeton-Hightstown Road, East Windsor, NJ 08520, Made in India, NDC 59651-617-08
- Lots / codes
Lot #: RB4023002A, Exp 02/2025
- Quantity
- 48 bottles
- Company
- Aurobindo Pharma USA Inc., East Windsor, NJ
- Distribution
- USA nationwide
- Initiated
- July 21, 2023 · Voluntary: Firm initiated
- Classified
- August 18, 2023
- Reported
- August 30, 2023
- Ended
- February 26, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Rufinamide
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.